Lifebit Raises $60M to Advance Federated Genomic Data Analysis

The Potential of Genomic Data in Precision Medicine

Genomic data is increasingly recognized as fundamental to the advancement of what is known as “precision medicine”. Predictions indicate that approximately 500 million human genomes will be sequenced by the year 2025. However, currently, only a limited portion of this data is actively applied to the processes of drug discovery and personalized healthcare.

Lifebit's Role in Expanding Data Access

Lifebit is a prominent startup facilitating broader access to worldwide biomedical data, specifically for pharmaceutical research. The company has recently secured $60 million in funding, with Tiger Global Management leading the investment round.

Existing investors, including Eurazeo, Pentech Ventures, and Beacon Capital, also contributed to this funding.

Secure Data Federation Technology

Lifebit highlights its patented technology for federating genomic data. This allows researchers to derive more comprehensive insights while simultaneously maintaining robust data security. Concerns regarding privacy are frequently voiced in relation to genomic information, given its intensely personal nature.

Impact on Rare Disease Diagnosis

The integration of human genetic data into diagnostic procedures is shown to significantly improve outcomes for patients with rare diseases. It is estimated that accurate diagnoses are achieved up to five times more frequently when genetic data is utilized.

Consequently, “Clinico-genomic” databases hold substantial potential for transformative advancements in healthcare.

Key Clients and Partnerships

Lifebit has established a client base spanning both public and private sectors. Notable collaborations include the Hong Kong Genome Project and an artificial intelligence partnership with Boehringer Ingelheim, a leading pharmaceutical company based in Germany.

Furthermore, the company was awarded a contract by the U.K. government to support Genomics England’s operations.

Statements from Leadership

Dr. Maria Chatzou Dunford, CEO of Lifebit and a former bioinformatics researcher, stated: “Our core belief is that all biomedical data with the potential to save lives should be utilized. Current data handling practices are contributing to preventable deaths, and until now, it has been impossible to make distributed, highly sensitive biomedical data usable while ensuring its security and integrating it with other datasets.”

John Curtius, a Partner at Tiger Global, commented: “We have strong confidence in Lifebit’s innovative software solutions and their dedication to customer satisfaction. These factors will undoubtedly accelerate global adoption and facilitate breakthroughs in precision medicine.”